Skip to main content
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine logoLink to Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine
. 2021 Nov 1;17(11):2179–2185. doi: 10.5664/jcsm.9338

The influence of antidepressants and actigraphy-derived sleep characteristics on pediatric multiple sleep latency testing

Meghna P Mansukhani 1,✉, Swati Dhankikar 1, Suresh Kotagal 1,2, Bhanu Prakash Kolla 1,3
PMCID: PMC8636371  PMID: 34013880

Abstract

Study Objectives:

Research evaluating the influence of rapid eye movement suppressing antidepressants (REMS-AD) on multiple sleep latency test (MSLT) results and the value of performing actigraphy prior to this test in children and adolescents is lacking. We examined the impact of REMS-AD and actigraphy parameters on mean sleep latency (MSL) and sleep-onset REM episodes (SOREMs) on MSLT in a pediatric clinical sample.

Methods:

This was a retrospective chart review at a quarternary referral center. We identified 164 MSLTs conducted in patients aged less than 18 years between 2014 and 2017. Correlations between REMS-AD, self-reported sleep duration, actigraphy parameters, and each of the outcomes (MSL and SOREMs) were examined. Regression analyses accounting for clinical characteristics were performed.

Results:

Mean age of the sample was 11.9 ± 4.19 years, 62% were female, 28 (17%) were on REMS-AD (48% of whom were able to discontinue these medications prior to MSLT), and mean pediatric daytime sleepiness score was 21.7 ± 6.1. MSL was 11.27 ± 5.77 min and mean number of SOREMs 0.55 ± 1.04. Patients on a REMS-AD at initial assessment had fewer SOREMs compared to those not taking these medications (0.17 ± 0.19 vs 0.62 ± 0.09; P = .04); no difference was noted in MSL (10.36 ± 1.10 vs 11.47 ± 0.50; P = .36). Increased time in bed on actigraphy correlated with a longer MSL and fewer SOREMs (r = .23; P = .04 and r = .316; P = .004, respectively). Following regression analyses, use of REMS-AD continued to remain associated with fewer SOREMs; greater time in bed on actigraphy, but not self-reported sleep duration, was associated with a longer MSL (all P < .05).

Conclusions:

Clinicians should account for the use of REMS-AD and utilize actigraphy to determine time in bed while interpreting the results of a pediatric MSLT.

Citation:

Mansukhani MP, Dhankikar S, Kotagal S, Kolla BP. The influence of antidepressants and actigraphy-derived sleep characteristics on pediatric multiple sleep latency testing. J Clin Sleep Med. 2021;17(11):2179–2185.

Keywords: objective, measurement, sleep duration, sleep time, rapid eye movement suppressing, medications, psychiatric, sleep-onset rapid eye movement period


BRIEF SUMMARY

Current Knowledge/Study Rationale: Current American Academy of Sleep Medicine (AASM) practice parameters for the clinical use of multiple sleep latency testing (MSLT) recommend the use of sleep logs or actigraphy for a week prior to testing and discontinuation of REM suppressant antidepressant medications whenever possible. However, empirical evidence examining the utility of these recommendations in pediatric populations is limited.

Study Impact: This study demonstrated that pediatric patients on REM suppressing antidepressant medication at the time of the initial assessment had fewer number of SOREMs. Additionally, greater time spent in bed as assessed by actigraphy was associated with a longer MSL.

INTRODUCTION

Excessive sleepiness is common in pediatric populations, with prevalence estimates ranging from 4% in preadolescents to 20% in high school seniors.1–3 The multiple sleep latency test (MSLT) is the most commonly used objective measure to assess excessive sleepiness and is the gold standard test to diagnose central disorders of hypersomnolence.4 MSLT is well validated with good interrater and intrarater reliability. However, results can be affected by multiple factors, including age, prior insufficient sleep, other untreated sleep disorders, underlying psychiatric conditions as well as antidepressant, anxiolytic, sedative hypnotic, and other medications. Close attention needs to be paid to the conduct of the test prevent false positive or false negative results.5

The American Academy of Sleep Medicine (AASM) practice parameters for the clinical use of the MSLT state that sleep logs may be obtained for 1 week prior to MSLT and that the test must immediately follow polysomnography (PSG) recorded during the individual’s main sleep period.4 These guidelines help ensure that circadian rhythm sleep-wake disorders have been considered and an adequate amount of sleep has been obtained prior to the test. Prior research has indicated that actigraphy provides a more accurate assessment of time in bed and time asleep in the weeks prior to MSLT compared to sleep logs, which are prone to recall bias.6 In clinical practice, actigraphy is often obtained along with sleep logs, although this testing is not always covered by medical insurance companies. Additionally, the utility of actigraphy vs self-reported sleep duration prior to MSLT in pediatric populations has not been previously examined.

Furthermore, the practice parameters state that the MSLT should ideally be performed in the absence of the concurrent use of rapid eye movement (REM) suppressing medications, whenever possible. Although empiric data are lacking in the pediatric population, REM suppressing antidepressants (REMS-AD) are among the most common medications that sleep medicine providers discontinue prior to performing the MSLT due to their potential to affect the mean sleep latency (MSL) and the number of sleep-onset REM periods (SOREMs).7–9 This strategy can pose a significant challenge to providers evaluating children and adolescents with a history of mood disorders as there is a possible risk of relapse of depressive symptoms including suicidality.

The main aim of this retrospective study was to assess the impact of REMS-AD and actigraphy-derived sleep characteristics on MSL and SOREMs in pediatric patients undergoing a clinically indicated MSLT at our quarternary level academic center. We examined whether patients who were on REMS-AD at the time of the initial assessment differed from those who were not on these medications in terms of the MSL and the number of SOREMs on MSLT after accounting for clinical confounders. We also examined whether actigraphy-derived sleep parameters were more likely to be correlated with MSL and SOREMs compared to self-reported sleep duration after accounting for these confounders.

METHODS

Study population

The study was approved by the Institutional Review Board at Mayo Clinic (protocol number: 18-006798). We conducted a search for all patients younger than 18 years of age who underwent MSLT (Current Procedural Terminology code: 95805) at our institution between January 1, 2014, and December 31, 2017. All included patients or their guardians had provided written research authorization. Patients without research authorization on file and those who were pregnant or breastfeeding were excluded.

Procedures and definitions

Actigraphy was performed using the Respironics Actiwatch 2 and Respironics Spectrum Plus devices (Philips Healthcare, bend Oregon) with ambient light sensors. Data from actigraphy were downloaded by a registered polysomnographic technologist and rescored if necessary. PSG was conducted and scored by a registered polysomnographic technologist using the rules for children specified in the AASM manual, unless specified otherwise by the treating clinician.10 All actigraphy, PSG, and MSLT studies were reviewed and interpreted by a board-certified pediatric sleep medicine physician at the Center for Sleep Medicine, Mayo Clinic Rochester, Minnesota.

PSG was generally commenced the same day that actigraphy testing was completed. MSLT was performed on the day following overnight PSG. MSLTs were conducted in accordance with the AASM practice parameters.4 Additionally, the following routine instructions and methodology were applicable to pediatric MSLTs performed at our institution. The decision to taper and discontinue medications that could potentially affect MSLT results was usually made by the pediatric sleep medicine provider after consulting with the patient’s primary care provider and/or psychiatrist; the schedule for the taper and/or interim prescriptions was provided by 1 of these providers, with the goal to discontinue these medications 2 weeks prior to testing (6 weeks in the case of fluoxetine due its long half-life11). Patients and their guardians were instructed to follow their regular sleep schedule preceding and during the period of testing, aiming for at least the minimum recommended sleep duration for their age. Actigraphy was performed for 2 weeks, and the patient or guardian was requested to complete the accompanying sleep logs. In most cases, the patient was seen in clinic when the actigraph was returned to discuss results prior to undergoing PSG. A minimum of 420 minutes of sleep, apnea-hypopnea index (AHI) < 1 event/h, and periodic limb movements not associated with significant sleep fragmentation were generally required on PSG to proceed with the subsequent MSLT. A pediatric sleep medicine physician reviewed and interpreted the actigraphy and PSG data prior to making the decision to proceed with MSLT. If titration of positive airway pressure was performed on PSG, the MSLT was canceled. Patients were required to abstain from caffeine on the day of MSLT. A fifth test nap opportunity was conducted at the discretion of the ordering provider; usually this was performed if there was 1 SOREM noted during the previous 4 test nap opportunities. All self-administered medications during the test were monitored and documented. Patients were advised to stop smoking 30 minutes before each test nap opportunity. Exposure to direct sunlight and activity was minimized, with no exposure for 15 minutes before each test. Patients had a urine drug screen ordered to be done on the morning of MSLT, aimed at detecting the use of illicit drugs as well as prescription medications.

Data abstraction

All data were obtained by manual review of the electronic medical record. Demographic and clinical characteristics included age, sex, body mass index (BMI), presenting symptoms at the time of sleep medicine consultation, self-reported sleep duration including naps, and medications: antidepressants (categorized into REMS-AD and not REM suppressing), benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonists and other sedative hypnotics. Actigraphy parameters included days of recording, mean time in bed (TIBa) and mean total sleep time (TSTa) for the entire recording period. PSG measures were total sleep time, sleep efficiency, sleep onset latency, initial REM latency (and presence of a SOREM, if applicable), periodic limb movement index, arousal index, and AHI. The MSL and number of SOREMs were extracted from MSLT.

Statistical analyses

Data were reported as means (± standard deviation) or medians (range), depending on the normality of data distribution. Statistical analyses were conducted examining correlations of MSL and number of SOREMs to self-reported sleep duration, actigraphy data, and use of REMS-AD with MSL and number of SOREMs as the dependent variables. The periodic limb movement index for the majority of the sample was 0 per hour, hence it was excluded from the analysis. Additional exploratory analyses were performed to evaluate differences in MSL and number of SOREMs among patients who were on REMS-AD but tapered the medication prior to the MSLT and those who remained on REMS-AD at the time of MSLT. Due to the small number of participants in each of these categories, the results should be considered preliminary. Correlations between other clinical, demographic, and PSG characteristics and the MSL and number of SOREMs were also explored to identify other potential factors that were associated with these outcomes.

Regression analyses examining the association between actigraphy data, self-reported sleep duration, and use of REMS-AD and MSL and number of SOREMs were performed after accounting for demographic characteristics including age, sex, and BMI. An a priori decision was made not include initial REM latency and sleep onset latency on PSG in the regression analyses as these measures are strongly correlated with MSLT findings of MSL and number of SOREMs and likely influenced by similar confounders. As none of the PSG characteristics apart from initial REM latency and sleep onset latency were found to be associated with the MSL and number of SOREMs, they were not included in the final regression analyses. All analyses were conducted utilizing JMP Statistical Analysis System version 9.4M3. The alpha level was set at 0.05 for statistical significance.

RESULTS

Baseline characteristics

A total of 164 unique patients were included in the final cohort. Demographics and symptoms at the time of presentation are shown in Table 1. The mean age of the cohort was 11.9 ± 4.19 years; 62% were female. Mean pediatric daytime sleepiness score was 21.7 ± 6.1.

Table 1.

Baseline patient characteristics.

Characteristic Mean SD
Age (years) 11.9 4.19
Sex (% female) 62 –
BMI (kg/m2) 21.9 5.6
PDSS 21.7 6.1
ESS 13.5 0.7
Self-reported sleep duration (h) 10.4 2.6
Shift work (%) 0 –
Present, n (%) Absent, n (%)
Cataplexy 24 (15) 132 (84)
Hypnagogic hallucinations 15 (9) 141 (87.5)
Hypnopompic hallucinations 12 (7.4) 144 (89.4)
Sleep paralysis 21 (13) 135 (84)
Dream enactment behavior 4 (2) 157 (96)
Insomnia 11 (7) 151 (92)
Depression 8 (5) 152 (93)
REMS-ADa 28 (17) 129 (80)
Antidepressant, not REM suppressingb 4 (2.5) 152 (94.4)
Stimulantc 16 (10) 136 (84.5)
Benzodiazepined 4 (2.5) 152 (94.4)
nBBRA 0 (0) 164 (100)
Actigraphy data 84 (52) 73 (45)
PSG data 154 (95) 5 (3)
MSLT data 164 (100) 0 (0)
PAP on MSLT 4 (2) 153 (95)
UDS results 102 (65) 53 (33)
a

Tapered in 48%. bNot tapered. cTapered in 61%, not tapered in 22%, unknown status in the remainder. dTapered in 100%. BMI = body mass index, ESS = Epworth Sleepiness Scale, MSLT = multiple sleep latency test, nBBRA = nonbenzodiazepine benzodiazepine receptor agonist, PAP = positive airway pressure, PDSS = Pediatric Daytime Sleepiness Scale, PSG = polysomnography, REM = rapid eye movement, REMS-AD = rapid eye movement suppressing antidepressant, SD = standard deviation, UDS = urine drug screen.

Actigraphy, PSG, and MSLT results are presented in Table 2. MSL was 11.27 ± 5.77 minutes for the entire cohort, and mean number of SOREMs was 0.55 ± 1.04. One patient had a SOREM on PSG; this patient also had 4 SOREMs on MSLT and the PSG SOREM did not impact the diagnoses or other results of this study. A total of 74 (45%) patients had an MSL ≤ 8 min on MSLT and 12 (7.3%) of these patients had ≥ 2 SOREMSs. Twenty-eight patients (17%) in the entire cohort were on REMS-AD, and 8 (48%) of these patients were able to discontinue these medications completely prior to the MSLT. While information on the specific indication for the use of a REMS-AD was not available, of the 28 patients, 18 had a diagnosis of a depressive disorder, 2 had a diagnosis of an anxiety disorder, and 2 patients had both depressive and anxiety disorder. The urine drug screen did not reveal the use of any illicit drugs, stimulants, or benzodiazepines in the study population at the time of the MSLT and confirmed that all patients who were asked to discontinue REMS-AD had in fact discontinued the medication.

Table 2.

Actigraphy and PSG results.

Mean SD
Actigraphy
 Days of recording 13.6 2.9
 TST (hours) 8.4 1.5
 TIB (hours) 9.7 1.4
 SE (%) 68.0 38.0
PSG
 TST (min) 482.2 54.7
 SE (%) 92.2 35.9
 SOL (min) 13.6 15.8
 Initial REM latency (min) 123.5 72.0
 AI (events per hour) 11.15 5.7
 AHI (events per hour) 1.8 3.8
MSLT
 MSL (min) 11.3 5.8
 Number of SOREMs 0.6 1.0
 SL1 (min) 9.6 6.9
 SL2 (min) 10.7 7.1
 SL3 (min) 12.1 11.8
 SL4 (min) 13.4 7.2
 SL5 (min)a 12.3 6.8

aPerformed in 9 patients. AHI = apnea-hypopnea index, AI = arousal index, MSL = mean sleep latency, SD = standard deviation, SE = sleep efficiency, SL1 = sleep latency on the first test nap opportunity, SL2 = sleep latency on the second test nap opportunity, SL3 = sleep latency on the third test nap opportunity, SL4 sleep latency on the fourth test nap opportunity, SL5 = sleep latency on the fifth test nap opportunity, SOL = sleep onset latency, SOREM = sleep-onset rapid eye movement, TIB = time in bed, TST = total sleep time.

Univariate analyses

Results of the univariate analyses are detailed in Table 3. Patients who were on REMS-AD at the time of the initial assessment had fewer SOREMs than those who were not on REMS-AD (0.18 ± 0.19 vs 0.62 ± 0.09; P = .03). There was no significant difference in MSL in those on a REMS-AD vs those not prescribed this medication (11.47 ± 0.50 vs 10.36 ± 1.10; P = .36).

Table 3.

Univariate analyses.

Characteristic MSL SOREM
Correlation P Correlation P
Age −0.325 .0001* 0.184 .02*
Sex**
 Male 11.88 ± 0.74 .31 0.58 ± 0.13 .83
 Female 10.85 ± 0.56 0.53 ± 0.10
BMI −0.215 .006* 0.228 .003*
PDSS −0.032 .76 −0.124 .257
Self-reported sleep duration −0.134 .09 −0.307 .001*
TIBa 0.231 .04* −0.316 .004*
TSTa 0.202 .06 −0.255 .02*
TSTp 0.015 .84 −0.153 .06
SE 0.028 .72 0.074 .36
SOL −0.170 .03* −0.005 .95
Initial REM latency −0.209 .008* −0.22 .005*
AHI −0.015 .85 0.118 .14
SOREM −0.417 .0001*
MSL −0.076 .34
REMS-AD**
 Yes 11.47 ± 0.50 .36 0.18 ± 0.19 .03*
 No∞ 10.36 ± 1.10 0.62 ± 0.09
*

P < .05. **One-way ANOVA. ∞Not on REMS-AD at the time of initial assessment. AHI = apnea-hypopnea index, AI = arousal index, BMI = body mass index, MSL = mean sleep latency, PDSS = Pediatric Daytime Sleepiness Scale, SE = sleep efficiency on polysomnography, SOL= sleep onset latency on polysomnography, SOREM = sleep-onset rapid eye movement period on multiple sleep latency test, TIBa = time in bed on actigraphy, TSTa = total sleep time on actigraphy, TSTp = total sleep time on polysomnography.

Longer self-reported sleep duration was associated with a fewer number of SOREMs (r = − .307; P = .001) but not with MSL (r = − .134; P = .09). In terms of actigraphy data, increasing TIBa was associated with a prolonged MSL (r = .23; P = .04) and fewer SOREMs (r = − .316; P = .004); greater TSTa was also associated with fewer SOREMs (r = − .255; P = .02) but not with MSL (r = .02; P = .06).

Among PSG characteristics, shorter sleep onset latency and initial REM latency were associated with lower MSL, while greater arousal index and shorter initial REM latencies were associated with a higher number of SOREMs. Increasing age and BMI were both correlated with a shorter MSL and higher number of SOREMs.

There was no difference in the number of SOREMs (0.15 ± 0.14 vs 0.25 ± 0.14; P = .83) or MSL (10.03 ± 1.73 vs 9.47 ± 1.66; P = .97) in those who remained on REMS-AD (20/28; 72%) compared to those who tapered and discontinued the medication (8/28; 28%) prior to testing.

Multiple regression analyses

In multiple regression analyses accounting for age, sex, and BMI, being on a REMS-AD at initial assessment continued to remain associated with having fewer SOREMs (Table 4). Following similar regression analyses, greater TIBa continued to remain associated with a longer MSL, while TSTa was no longer associated with MSL or SOREMs. Self-reported sleep duration was also no longer associated with MSL or SOREMs.

Table 4.

Multiple regression analyses.

MSL SOREMs
Estimate Standard Error P Estimate Standard Error P
TSTa 0.55 0.41 .18 −0.05 0.07 .46
TIBa 0.87 0.41 .04* −0.10 0.07 .19
Self-reported sleep duration −0.41 0.16 .16 0.02 0.03 .55
REMS-AD −0.08 0.59 .89 −0.25 0.11 .02*

*P < .05. Regression model accounting for age, sex, and body mass index. MSL = mean sleep latency, REMS-AD = rapid eye movement suppressing antidepressant, SOREM = sleep-onset rapid eye movement period on multiple sleep latency test, TIBa = time in bed on actigraphy, TSTa = total sleep time on actigraphy.

DISCUSSION

The AASM recommendations on the conduct of the MSLT are largely based on expert opinion and restricted in scope to adults due to a paucity of studies examining the impact of factors that could influence MSLT results in younger children. Specifically, controlled studies performed in participants with and without antidepressant medication use at the time of MSLT are lacking and the influence of objectively assessed sleep parameters on MSLT results are unknown. The findings from our retrospective study indicate that being on a REMS-AD at the time of assessment can influence the number of SOREMs and demonstrate the utility of performing objective testing with actigraphy prior to MSLT.

Depression is common in the pediatric population, with 12-month period prevalence estimates of approximately 1–2% in prepubertal children and 4–5% in postpubertal adolescents.12,13 Depression tends to be a highly remitting and relapsing condition; relapse rates in the pediatric age groups range between 34 and 75% with combination psychotherapy and medication treatment.14 Additionally, depression has been shown to be associated with shorter REM latencies and complaints of excessive sleepiness.1,15 Therefore, discontinuing these medications prior to MSLT in the pediatric population is a complex issue and empirical data are required to help support clinicians in the medical decision-making process.

Antidepressants with REM-suppressing properties can increase the latency to the first episode of REM sleep and decrease the overall percentage of REM sleep.8,9 There are sparse data examining the effects of antidepressants on sleep in the pediatric population. Discontinuation of REMS-AD prior to MSLT has been shown to be associated with a greater number of SOREMs in adults.16 In our sample, patients who were on REMS-AD were likely to have fewer SOREMs and this association persisted after regression analyses accounting for age, sex, and BMI. About half of our sample discontinued their REMS-AD prior to their MSLT. Exploratory analyses in our study indicated that those who discontinued their medications were more likely to have SOREMs than those who remained on them; however, this was not statistically significant. Research in adult populations with larger numbers have revealed that patients who taper REMS-AD prior to MSLT have greater number of SOREMS compared to those who continued taking them at the time of testing.16 Future studies involving larger pediatric samples should attempt to answer the question of whether discontinuing medications prior to testing can indeed result in an increase in the number of SOREMs on MSLT.

While the AASM practice parameters for the performance of MSLT recommend the use of sleep logs, a more recent practice guideline suggested that actigraphy assures adequate sleep time prior to testing and can help determine habitual sleep-wake times.17 Additionally, actigraphy is completed more reliably compared to sleep logs.18 A recent meta-analysis indicated that actigraphy and sleep logs provide distinct pieces of information when assessing TST.19 There was a significant difference between self-reported sleep duration and actigraphy-determined total sleep time noted in a study conducted in a pediatric sample.6 It is quite likely that in the case of children and adolescents, sleep logs are completed by parents and that estimates of sleep time may be largely inaccurate. Therefore, in the pediatric population, actigraphy may be particularly helpful in establishing sleep-wake routines and estimating the total time in bed.

In our study, TIBa was correlated with MSL and the number of SOREMs. TIBa continued to remain associated while self-reported sleep duration and TSTa were not associated with MSL in regression analyses. Similar to previous studies, self-reported sleep duration was noted to be greater than TSTa.20,21 Based on our data, TIBa appears to be better correlated with MSLT findings in a pediatric population compared to TSTa. Actigraphy determines total sleep time based on reduced movement.22 In populations where sleep is likely be disrupted, such as insomnia or narcolepsy, increased movement during the nighttime could potentially lead to erroneous measures of TSTa.23–25 Therefore, TIBa is likely a more accurate measure to help determine whether patients have obtained overall sufficient sleep in the weeks prior to MSLT to proceed with the test.

Our study has several strengths. This is the first investigation assessing the impact of REMS-AD and objective assessments from actigraphy on MSL and SOREMs in the pediatric population. Our study included a fairly large sample of pediatric patients undergoing comprehensive evaluation for excessive sleepiness with complete data available for the main outcomes of interest. Clinical data and urine drug screen results were available in a majority of patients and the latter confirmed the absence of other medications or illicit drugs.

There are several limitations that need to be considered, including selection bias that is unavoidable in a clinical sample of patients referred to a quarternary-level academic center for evaluation of excessive sleepiness. The methodology of testing and clinical management of cases may be unique to the pediatric sleep medicine physicians at our center, reducing generalizability of the findings. This study was retrospective in nature and has all the potential biases inherent to this type of investigation, and the specific indications for the use of REMS-AD in each patient and systematic information about additional comorbidities were not available. A significant proportion of the cohort was on antidepressant medication, allowing for analysis of the impact of these medications on MSLT results; however, further analyses conducted with regard to discontinuation of REMS-AD may not be meaningful due to the smaller numbers of patients in each category and should be considered preliminary in nature. Additionally, clinical factors may have influenced the decision to taper medications and this in turn could have affected the results of the analysis. Finally, there may have been some confounders such as circadian sleep-wake rhythm disorders common in adolescents that were unaccounted for, although this seems unlikely given that all patients had a comprehensive sleep medicine consultation and underwent actigraphy prior to the MSLT.

CONCLUSIONS

The AASM practice parameters recommend conducting the MSLT without the use of REM-suppressing medication if possible and suggest the use of sleep logs prior to the test. These recommendations are based on expert consensus, and there are no previous studies to help guide these recommendations in patients under the age of 18 years. Ours is the first investigation assessing the impact of these medications and actigraphy-derived sleep parameters in pediatric patients undergoing an MSLT after actigraphy and PSG for the indication of excessive sleepiness. This study demonstrated that the use of REM suppressing antidepressant medication may reduce the number of SOREMs. Additionally, greater time spent in bed as assessed by actigraphy is associated with a longer MSL. Clinicians should consider these factors while interpreting MSLTs, and future prospective studies should examine whether discontinuing these medications prior to testing in a large sample results in increased sensitivity of the test.

ABBREVIATIONS

AASM

American Academy of Sleep Medicine

AHI

apnea-hypopnea index

BMI

body mass index

MSL

mean sleep latency

MSLT

multiple sleep latency test

PSG

polysomnography

REM

rapid eye movement

REMS-AD

rapid eye movement suppressing antidepressant(s)

SOREM

sleep-onset rapid eye movement

TIB

time in bed

TST

total sleep time

DISCLOSURE STATEMENT

All authors have seen and approved this manuscript. Dr. Mansukhani was the principal investigator on a research grant funded by ResMed Foundation (2016–2019) and the recipient of the Paul and Ruby Tsai and Family Fund Career Development Award (2017–2020) at Mayo Clinic, which are not relevant to the current work. The other authors report no conflicts of interest.

REFERENCES

  • 1. Kolla BP, He JP, Mansukhani MP, Kotagal S, Frye MA, Merikangas KR . Prevalence and correlates of hypersomnolence symptoms in US teens . J Am Acad Child Adolesc Psychiatry. 2019. ; 58 ( 7 ): 712 – 720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Pagel JF, Forister N, Kwiatkowki C . Adolescent sleep disturbance and school performance: the confounding variable of socioeconomics . J Clin Sleep Med. 2007. ; 3 ( 1 ): 19 – 23 . [PubMed] [Google Scholar]
  • 3. Campbell IG, Burright CS, Kraus AM, Grimm KJ, Feinberg I . Daytime sleepiness increases with age in early adolescence: a sleep restriction dose-response study . Sleep. 2017. ; 40 ( 5 ): zsx046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Littner MR, Kushida C, Wise M, et al. ; Standards of Practice Committee of the American Academy of Sleep Medicine . Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test . Sleep. 2005. ; 28 ( 1 ): 113 – 121. [DOI] [PubMed] [Google Scholar]
  • 5. Carskadon MA, Dement WC, Mitler MM, Roth T, Westbrook PR, Keenan S . Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness . Sleep. 1986. ; 9 ( 4 ): 519 – 524. [DOI] [PubMed] [Google Scholar]
  • 6. Holley S, Hill CM, Stevenson J . A comparison of actigraphy and parental report of sleep habits in typically developing children aged 6 to 11 years . Behav Sleep Med. 2010. ; 8 ( 1 ): 16 – 27. [DOI] [PubMed] [Google Scholar]
  • 7. Busková J, Kemlink D, Ibarburu V, Nevsímalová S, Sonka K . Antidepressants substantially affect basic REM sleep characteristics in narcolepsy-cataplexy patients . Neuroendocrinol Lett. 2015. ; 36 ( 5 ): 430 – 433 . [PubMed] [Google Scholar]
  • 8. Doghramji K, Jangro WC . Adverse effects of psychotropic medications on sleep . Psychiatr Clin North Am. 2016. ; 39 ( 3 ): 487 – 502. [DOI] [PubMed] [Google Scholar]
  • 9. Zhang B, Hao Y, Jia F, et al . Sertraline and periodic limb movements during sleep: an 8-week open-label study in depressed patients with insomnia . Sleep Med. 2013. ; 14 ( 12 ): 1405 – 1412. [DOI] [PubMed] [Google Scholar]
  • 10. Berry RB, Budhiraja R, Gottlieb DJ, et al. ; Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine . Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events . J Clin Sleep Med. 2012. ; 8 ( 5 ): 597 – 619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Food and Drug Administration . Label for Prozac (fluoxetine). https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018936s076lbl.pdf . Published 2006. Accessed March 12, 2021.
  • 12. Thapar A, Collishaw S, Pine DS, Thapar AK . Depression in adolescence . Lancet. 2012. ; 379 ( 9820 ): 1056 – 1067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Egger HL, Angold A . Common emotional and behavioral disorders in preschool children: presentation, nosology, and epidemiology . J Child Psychol Psychiatry. 2006. ; 47 ( 3-4 ): 313 – 337. [DOI] [PubMed] [Google Scholar]
  • 14. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Carmody T, Mayes TL . Fluoxetine in child and adolescent depression: acute and maintenance treatment . Depress Anxiety. 1998. ; 7 ( 1 ): 32 – 39. [DOI] [PubMed] [Google Scholar]
  • 15. Palagini L, Baglioni C, Ciapparelli A, Gemignani A, Riemann D . REM sleep dysregulation in depression: state of the art . Sleep Med Rev. 2013. ; 17 ( 5 ): 377 – 390. [DOI] [PubMed] [Google Scholar]
  • 16. Kolla BP, Jahani Kondori M, Silber MH, Samman H, Dhankikar S, Mansukhani MP . Advance taper of antidepressants prior to multiple sleep latency testing increases the number of sleep-onset rapid eye movement periods and reduces mean sleep latency . J Clin Sleep Med. 2020. ; 16 ( 11 ): 1921 – 1927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Smith MT, McCrae CS, Cheung J, et al . Use of actigraphy for the evaluation of sleep disorders and circadian rhythm sleep-wake disorders: an American Academy of Sleep Medicine clinical practice guideline . J Clin Sleep Med. 2018. ; 14 ( 7 ): 1231 – 1237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Auger RR, Varghese R, Silber MH, Slocumb NL . Total sleep time obtained from actigraphy versus sleep logs in an academic sleep center and impact on further sleep testing . Nat Sci Sleep. 2013. ; 5 : 125 – 131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Smith MT, McCrae CS, Cheung J, et al . Use of actigraphy for the evaluation of sleep disorders and circadian rhythm sleep-wake disorders: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment . J Clin Sleep Med. 2018. ; 14 ( 7 ): 1209 – 1230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Iwasaki M, Iwata S, Iemura A, et al . Utility of subjective sleep assessment tools for healthy preschool children: a comparative study between sleep logs, questionnaires, and actigraphy . J Epidemiol. 2010. ; 20 ( 2 ): 143 – 149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Wolfson AR, Carskadon MA, Acebo C, et al . Evidence for the validity of a sleep habits survey for adolescents . Sleep. 2003. ; 26 ( 2 ): 213 – 216. [DOI] [PubMed] [Google Scholar]
  • 22. Sadeh A . The role and validity of actigraphy in sleep medicine: an update . Sleep Med Rev. 2011. ; 15 ( 4 ): 259 – 267. [DOI] [PubMed] [Google Scholar]
  • 23. Hauri PJ, Wisbey J . Wrist actigraphy in insomnia . Sleep. 1992. ; 15 ( 4 ): 293 – 301. [DOI] [PubMed] [Google Scholar]
  • 24. Johnson NL, Kirchner HL, Rosen CL, et al . Sleep estimation using wrist actigraphy in adolescents with and without sleep disordered breathing: a comparison of three data modes . Sleep. 2007. ; 30 ( 7 ): 899 – 905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Filardi M, Pizza F, Bruni O, Natale V, Plazzi G . Circadian rest-activity rhythm in pediatric type 1 narcolepsy . Sleep. 2016. ; 39 ( 6 ): 1241 – 1247. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine are provided here courtesy of Springer

RESOURCES